Cognitive DeclineNCT03839784
Building a Platform for Precision Anesthesia in the Geriatric Surgical Patient
An observational study of Cognitive Decline and Cognitive Change, run by Stanford University at 1 site in United States.
Trial summary
The research team is creating a foundational infrastructure in order to develop a precision medicine approach for geriatric patients who require surgery with anesthesia. The team plans to build the first of its kind comprehensive database of demographic and risk factor questionnaire responses, biobanked blood… Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Cognitive Decline, Cognitive Change, Cognitive Impairment
- What is being tested?
- Neurocognition Interventions
- How many people
- 250 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2020to 30 Aug 2030
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Stanford Hospital geriatric patients having surgery.
Who may be able to join
- At least 65 years old (inclusive)
- Non cardiac general elective surgery
- General anesthesia is expected for 2+ hours
Who cannot join
- Alzheimer's
- Dementia
- Parkinson's
- History of neurodegenerative diseases
- Medication for depression (ie. Benzodiazepines)
- Alcoholism
- Discretion of PI
Trial locations and contacts
1 site in 1 country.
About this study
The research team is creating a foundational infrastructure in order to develop a precision medicine approach for geriatric patients who require surgery with anesthesia. The team plans to build the first of its kind comprehensive database of demographic and risk factor questionnaire responses, biobanked blood specimens, intraoperative electroencephalography (EEG), and inclusive cognitive testing throughout patient interaction starting at the preop appointment until a year later. This will be used to create a predictive model of periooperative neurocognitive disorders.
- Conditions
- Cognitive Decline, Cognitive Change, Cognitive Impairment, Postoperative Delirium, Anesthesia; Reaction, Anesthesia; Adverse Effect
- Being tested
- Neurocognition Interventions
- Medical subject headings
- Cognitive Dysfunction, Emergence Delirium
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neurocognition InterventionsCombination product
EEG, Neurocognitive Battery Testing, and Immune Profiles
| Study group | Role | What they receive |
|---|---|---|
| Neurocognitive Assessment Arm | Not described Receives: Combination Product: Neurocognition Interventions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Neurocognitive Disorders
Neurocognitive Assessment Battery
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2019
- Study start1 Sep 2020
- Primary completion30 Aug 2030 (estimated)
- Study completion30 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive DeclineStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 250 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, David R. Drover, Stanford University
- Investigators
- David Drover, MD, Principal investigator, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03839784
- Sponsor's protocol ID
- 55169
- Status last verified
- Apr 2026
- First submitted
- 11 Feb 2019
- Last updated
- 23 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Building a Platform for Precision Anesthesia in the Geriatric Surgical Patient
- ClinicalTrials.gov ID
- NCT03839784
- Acronym / sponsor ID
- 55169
- Conditions
- Cognitive Decline, Cognitive Change, Cognitive Impairment, Postoperative Delirium, Anesthesia; Reaction, Anesthesia; Adverse Effect
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Study start
- 1 Sep 2020 (actual)
- Primary completion
- 30 Aug 2030 (estimated)
- Study completion
- 30 Aug 2030 (estimated)
- First posted
- 15 Feb 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The research team is creating a foundational infrastructure in order to develop a precision medicine approach for geriatric patients who require surgery with anesthesia. The team plans to build the first of its kind comprehensive database of demographic and risk factor questionnaire responses, biobanked blood specimens, intraoperative electroencephalography (EEG), and inclusive cognitive testing throughout patient interaction starting at the preop appointment until a year later. This will be used to create a predictive model of periooperative neurocognitive disorders.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Neurocognitive Assessment Arm | – | Combination Product: Neurocognition Interventions |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Stanford Hospital geriatric patients having surgery.
Key inclusion criteria (3 listed)
- At least 65 years old (inclusive)
- Non cardiac general elective surgery
- General anesthesia is expected for 2+ hours
Key exclusion criteria (7 listed)
- Alzheimer's
- Dementia
- Parkinson's
- History of neurodegenerative diseases
- Medication for depression (ie. Benzodiazepines)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neurocognition InterventionsEEG, Neurocognitive Battery Testing, and Immune Profiles | Combination product | Neurocognitive Assessment Arm |
Primary outcome
Postoperative Neurocognitive Disorders
Time frame: 3 years
Neurocognitive Assessment Battery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cognitive Decline
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Not yet recruitingObservational study
Detecting and Predicting Post-stroke Cognitive Impairment Using the Oxford Cognitive Screen
Stroke, Ischemic Stroke
RecruitingPhase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Parkinson's Disease, Dementia
Recruiting
HOBSCOTCH-MS-Efficacy Trial
Multiple Sclerosis, Cognitive Dysfunction
Recruiting
Buddy-Up Dyadic Physical Activity Program for Persons With Dementia and Family Caregivers
Cognitive Impairment, Mild, Dementia, Mild
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Drover, MD principal investigator
Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cognitive Decline and Cognitive Change, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Neurocognitive Disorders (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2026.